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Avemar, a product of industrial fermentation of wheat germ with a standardized content of benzoquinone and plant ﬂavonoids,
has been tested as an anti-cancer and immunomodulatory dietary supplement. Proposed mechanisms include anti-oxidant
and anti-inﬂammatory actions. This study has determined whether these actions of Avemar may also be useful in the
treatment of cardiovascular diseases. Two experimental rat models of cardiovascular remodeling were used in this project: the
deoxycorticosteroneacetate(DOCA)-salt-inducedmodelofchronichypertension(studyI)andahigh-carbohydrate/high-fatdiet-
induced model producing chronic symptoms of the metabolic syndrome and its associated cardiovascular complications (study
II). Our results in these rat models of hypertension and diet-induced obesity show that treatment with Avemar improved cardiac
function, decreased macrophage inﬁltration resulting in decreased collagen deposition in the ventricular myocardium, reversed
an increased stiﬀness of the left ventricle in the diseased hearts and attenuated increased plasma malondialdehyde concentrations.
In addition to the changes in the heart, Avemar reversed glucose intolerance, normalized systolic blood pressure and decreased
visceral fat deposition in rats fed a high-fat/high-carbohydrate diet. In conclusion, the fermented wheat germ extract Avemar has a
potential role in attenuating chronic hypertension, diabetes or metabolic syndrome-induced cardiovascular symptoms along with
metabolic abnormalities such as glucose tolerance and obesity.
1.Introduction
Avemar is a product of industrial fermentation of wheat
germwithastandardizedcontentofbenzoquinoneandplant
ﬂavonoids that has been reported as safe and eﬀective as
an anti-cancer and immunomodulatory dietary supplement
[1–6]. Avemar beneﬁted patients with stage III melanoma
or colorectal cancer by increasing progression-free survival
[1, 3]. Avemar supplementation reduced the incidence
of treatment-related febrile neutropenia in children with
solid cancers [7]. Avemar is currently being evaluated as
a potential adjuvant therapeutic agent in human cancers,
including those of the breast, colon, lung and prostate, with
promising results as a supportive therapy with current anti-
cancer therapies [3, 7–9]. Preliminary results with Avemar
supplementation in severe rheumatoid arthritis patients
showed improved quality of life after 6 and 12 months of
treatment compared with baseline measurements [10, 11].
Plants have provided many possible treatment options
for human hypertension and metabolic diseases [12–17]. As
with this wheat germ extract, the ingredients of the plant
extracts responsible for the therapeutic responses are usually
not known. The mechanisms which could possibly explain
the responses to wheat germ extract include inhibition of
poly(ADP-ribose) polymerase (PARP), decrease in MHC
class I molecules, up-regulation of intercellular adhesion
molecule-1 (ICAM-1), regulation of pentose phosphate
pathway, inhibition of cyclooxygenase isoforms and up-
regulation of endogenous antioxidants [3, 6, 9, 18, 19].
These mechanisms may also be relevant for the treatment
of cardiovascular and metabolic diseases. Decreased antiox-
idant concentrations resulting in oxidative stress may play
an important role in the etiology of the symptoms of car-
diovascular remodeling such as hypertension and hypertro-
phy; these antioxidant concentrations may be improved by
nutraceuticals [20, 21]. Selective cyclooxygenase and PARP
inhibitors as well as antioxidant compounds have improved
cardiovascular function in myocardial ischemia/reperfusion
injury, heart failure, cardiomyopathies, circulatory shock,
cardiovascular aging, diabetic cardiovascular complications,2 Evidence-Based Complementary and Alternative Medicine
myocardialhypertrophy,atherosclerosisandvascularremod-
eling following injury [22–24].
Since the progression of cardiac remodeling and
metabolic diseases is characterized by oxidative stress and
chronic inﬂammation, it is possible that Avemar decreases
cardiovascular remodeling, glucose intolerance and fat
deposition through its reported anti-oxidant and anti-
inﬂammatoryproperties.Thus,wehaveinvestigatedwhether
dietary treatment with Avemar can regulate cardiovascular
remodeling and metabolic responses in hypertensive and
diet-induced obese rats. Structural changes in the heart were
characterized by histology and echocardiography, whereas
heart function was measured in vivo using echocardiography
andexvivoinisolatedperfusedhearts.Isolatedthoracicrings
were used to measure vascular reactivity.
2. Methods
2.1. Male Wistar Rats. Male Wistar rats were bred at
The University of Queensland Biological Resources facility.
All experimental protocols were approved by the Animal
Experimentation Ethics Committee of The University of
Queensland, under the guidelines of the National Health and
Medical Research Council of Australia. Rats were given ad
libitum access to food and water and were housed in 12-h
light/dark conditions. Body weight, food and water intakes
were measured daily. Two experimental models of cardio-
vascular remodeling were used in this project: the deoxycor-
ticosterone acetate (DOCA)-salt-induced model of chronic
hypertension (study I) and a high-carbohydrate/high-fat
diet-induced model producing chronic symptoms of the
metabolic syndrome and its associated cardiovascular com-
plications (study II).
All the rats in study I were uninephrectomized (UNX).
Rats, 8-9 weeks old, were divided into four experimental
groups of eight rats each; UNX only or treated with Avemar
(4% mixture in powdered rat food; UNX+AVE) or UNX
together with DOCA (25mg in 0.4mL dimethylformamide
s.c. every fourth day) and 1% NaCl in the drinking
water, with or without Avemar treatment (DOCA and
DOCA+AVE groups). For uninephrectomy, rats were
anesthetized with an intraperitoneal injection of tiletamine
(25mg/kg) and zolazepam (25mg/kg, Zoletil) together
with xylazine (10mg/kg, Rompun); a lateral abdominal
incision provided access to the kidney, and the left renal
vessels and ureter were ligated. The left kidney was removed
and weighed, and the incision site was sutured. Avemar
treatment was started 4 days before surgery and continued
for 28 days until the experiments were performed (treatment
for 32 days).
Study II consisted of three experimental groups of
8-9 weeks old male Wistar rats treated for 16 weeks with
corn starch (CS) (n=12), cafeteria+beef tallow (CAF+
BT) (n=12) and cafeteria+beef tallow+Avemar (CAF+
BT+AVE) (n=12) protocol, respectively. The CAF+BT
diet consisted of fructose (175g), powdered rat food (155g),
beef tallow (200g), condensed milk (395g), Hubble, Mendel
and Wakeman salt mixture (25g) and water (50mL) per
kilogram of food. The drinking water in the CAF+BT-fed
rats was augmented with 25% fructose in the water. For the
control diet, fructose and condensed milk were replaced with
CS(575g)andBTwasreplacedwithwater(200mL).Avemar
was administered as a 4% mixture along with CAF+BT
diet for 8 weeks starting 8 weeks after the initiation of the
high-fat/high-carbohydrate diet (reversal protocol). Daily
caloric intake was calculated from the food and water intakes
using the following values (kJ/g): fructose, 15.4; CS, 15.9;
condensed milk, 13.8; BT, 37.7 and rat food, 13.5.
Systolic blood pressure was measured in study I rats
after 0, 2 and 4 weeks and in study II rats after 0, 4,
8, 12 and 16 weeks under light sedation with i.p. injec-
tion of Zoletil (tiletamine 15mg/kg, zolazepam 15mg/kg).
Measurements were taken using an MLT1010 Piezo-Electric
Pulse Transducer (ADInstruments, Sydney, Australia) and
inﬂatable tail-cuﬀ connected to a MLT844 Physiological
Pressure Transducer (ADInstruments) and PowerLab data
acquisition unit (ADInstruments).
Fasting blood glucose concentrations were measured
for study II animals with blood taken from the tail vein
using Medisense Precision Q.I.D glucose meter (Abbott
L a b o r a t o r i e s ,B e d f o r d ,U S A ) .T h er a t sw e r eg i v e n4 0 %
glucose solution in distilled water (2g/kg body weight) via
oral gavage. Tail vein blood samples were taken at 0, 30, 60,
90 and 120 min following glucose administration.
Plasma malondialdehyde concentrations as a measure of
oxidative stress were determined in post-mortem blood by
HPLC [26].
2.2. Echocardiography. Echocardiography was performed by
trained cardiac sonographers at the Small Animal Practice,
School of Veterinary Sciences, The University of Queensland
or The Prince Charles Hospital, Brisbane, small animal
theater. Rats were anesthetized via i.p. injection with Zoletil
(tiletamine15mg/kg,zolazepam15mg/kg)andIliumXylazil
(xylazine 10mg/kg). Echocardiographic images of rats were
obtained using the Hewlett Packard Sonos 5500 (12MHz
frequency fetal transducer) at an image depth of 3cm using
two focal zones. Measurements of left ventricular posterior
wall thickness and internal diameter were made using two-
dimensional M-Mode taken at mid-papillary level [25].
2.3. Isolated Heart Preparation. The left ventricular function
of the rats in all treatment groups was assessed using
the Langendorﬀ heart preparation. Terminal anesthesia
was induced via i.p. injection of pentobarbitone sodium
100mg/kg (Lethabarb). Once anesthesia was achieved, hep-
arin (1000IU) was injected into the right femoral vein. Iso-
volumetric ventricular function was measured by inserting a
latex balloon catheter into the left ventricle connected to a
Capto SP844 MLT844 physiological pressure transducer and
Chart software on a Maclab system. All left ventricular end-
diastolic pressure values were measured by pacing the heart
at 250 beats per minute using an electrical stimulator. End-
diastolic pressures were obtained starting from 0mmHg up
to30mmHg.Therightandleftventricleswereseparatedand
weighed. Diastolic stiﬀness constant (κ, dimensionless) was
calculated as in previous studies [26, 27].Evidence-Based Complementary and Alternative Medicine 3
Table 1: Physiological parameters of UNX, UNX+AVE, DOCA and DOCA+AVE-fed rats.
Parameter UNX (4 weeks) UNX+AVE (4 weeks) DOCA (4 weeks) DOCA+AVE (4 weeks)
Daily water intake (mL) 67±11 (n=6) 59±9( n=6) 190±33∗ (n=6) 125±30∗∗ (n=6)
Daily food intake (g) 29±2( n=6) 27±3( n=6) 24±5( n=6) 23±5( n=6)
Systolic blood pressure
(mmHg) 0 week 107±1.3 (n=6) 113±1.8 (n=6) 108±3.1 (n=6) 105±2.1 (n=6)
Systolic blood pressure
(mmHg) 2 weeks 128±0.7 (n=6) 145±6∗ (n=6) 176±7.0∗ (n=6) 171±6.0∗ (n=6)
Systolic blood pressure
(mmHg) 4 weeks 135±1.7 (n=6) 151±1.0∗ (n=6) 186±3.6∗ (n=6) 182±3.0∗ (n=6)
LVIDd (cm) 0.66 ±0.01 (n=6) 0.57±0.01∗ (n=6) 0.48±0.02∗ (n=6) 0.51±0.01∗ (n=6)
LVPWd (cm) 0.15 ±0.01 (n=6) 0.17±0.01 (n=6) 0.22±0.01∗ (n=6) 0.22±0.01∗ (n=6)
Fractional shortening (%) 54±6( n=6) 57±1.4 (n=6) 58±3( n=6) 64±5( n=6)
LV mass (g) 0.7 ±0.01 (n=6) 0.63±0.01 (n=6) 0.85±0.01∗ (n=6) 0.75±0.01∗∗ (n=6)
Cardiac output (mL/min) 56±9( n=6) 39±8( n=6) 21±3∗ (n=6) 27±8∗ (n=6)
Ejection fraction (%) 87±3( n=6) 92±0.7 (n=6) 92±2( n=6) 92±1.4 (n=6)
Relative wall thickness 0.49±0.01 (n=6) 0.94±0.2∗ (n=6) 1.49±0.68∗ (n=6) 0.94±0.2∗∗ (n=6)
LV—interstitial collagen
(% of total area) 2.7±0.3 (n=5) 2.4±0.5 (n=5) 11.7±1.3∗ (n=6) 3.8±0.7∗∗ (n=5)
LV—perivascular collagen
(% of total area) 25.6±0.9 (n=4) 26.2±1.1 (n=4) 36.4±1.3∗ (n=4) 28.1±1.0∗∗ (n=4)
Diastolic stiﬀness constant (κ) 20.3±0.8 (n=6) 19.7±1.8 (n=6) 32.3±1.7∗ (n=6) 22.6±0.7∗∗ (n=6)
LV+septum (mg/g body wt) 2.16±0.1 (n=6) 2.0±0.1 (n=6) 3.06±0.08∗ (n=6) 2.9±0.1∗ (n=6)
RV (mg/g body wt) 0.36±0.01 (n=6) 0.51±0.01∗ (n=6) 0.49±0.01∗ (n=6) 0.54±0.01∗ (n=6)
Liver (mg/g body wt) 28.2±1.7 (n=6) 40.6±1.4 (n=6) 54±2.0∗ (n=6) 45.6±3∗∗ (n=6)
Spleen (mg/g body wt) 2.4±0.17 (n=6) 2.4±0.1 (n=6) 4.3±0.2∗ (n=6) 3.1±0.1∗∗ (n=6)
Remnant kidney (mg/g body wt) 5.1±0.4 (n=6) 4.0±0.5 (n=6) 8.2±0.3∗ (n=6) 9.3±0.5∗ (n=6)
Plasma malondialdehyde
(MDA) concentration (μmol/L) 19.7±0.7 (n=6) 20.4±0.6 (n=6) 27.3±0.8∗ (n=6) 23.9±0.6∗∗ (n=6)
Values are mean±SEM; number of experiments in parentheses. LV, left ventricle; RV, right ventricle; LVIDd, left ventricular internal diameter at diastole;
LVPWd, left ventricular posterior wall thickness at diastole. LV mass calculated according to [25]. ∗P <.05 versus UNX; ∗∗P <.05 versus DOCA.
2.4. Organ Bath Studies. Thoracic aortic rings (4mm in
length) were suspended in an organ bath chamber with
a resting tension of 10mN. Cumulative concentration—
response (contraction) curves were measured for nora-
drenaline; concentration—response (relaxation) curves were
measured for acetylcholine and sodium nitroprusside in
the presence of a submaximal (70%) contraction to nora-
drenaline [28].
2.5. Organ Weights. Following euthanasia, the heart, liver,
kidneys, visceral fat pads and spleen were removed and
blotted dry for weighing. All organ weights except visceral fat
pads were normalized relative to the body weight at the time
of their removal (in mg/g). Visceral fat pads were normalized
relative to tibial length at the time of removal (in mg/mm).
2.6. Histology. Collagen distribution was measured in the
left ventricle following staining with picrosirius red and
analyzed by laser confocal microscopy. Tissues were initially
ﬁxed for 3 days in Telly’s ﬁxative (100mL of 70% ethanol,
5mL of glacial acetic acid and 10mL of 40% formaldehyde)
and then transferred into modiﬁed Bouin’s ﬂuid (85mL of
saturated picric acid, 5mL glacial acetic acid and 10mL
of 40% formaldehyde) for 2 days. The samples were then
dehydrated and embedded in paraﬃn wax. Thick sections
(15μm) were cut and stained with image analysis under the
laserscanningmicroscopeperformedaspreviouslydescribed
[26, 29]. Thin sections (10μm) of left ventricle were cut
and stained with hematoxylin and eosin for determination
of inﬂammatory cell inﬁltration.
2.7. Statistical Analysis. All data sets were represented as
mean±SEM. Comparisons or ﬁndings between groups were
made via statistical analysis of data sets using one-way/two-
way analysis of variance followed by the Duncan test to
determine diﬀerences between treatment groups. A P-value
<.05 was considered as statistically signiﬁcant.
2.8. Drugs. DOCA, heparin, noradrenaline, acetylcholine
and sodium nitroprusside were purchased from Sigma
Chemical Company (St Louis, MO, USA.) The fermented
wheat germ extract, Avemar, was provided by Jenny Blyth,
Medimpex Pty Ltd, Mudgeeraba, QLD 4213, Australia and
thoroughly mixed in the food to a ﬁnal concentration of
4%. Noradrenaline, acetylcholine and sodium nitroprusside
were dissolved in distilled water. DOCA was dissolved in4 Evidence-Based Complementary and Alternative Medicine
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 1:Picrosiriusredstainingofleftventricularinterstitialcollagendeposition(magniﬁcation, ×40)inUNX(a),DOCA(b),UNX+AVE
(c), DOCA+AVE (d)-treated rats and hematoxylin and eosin staining of inﬁltrating inﬂammatory cells of left ventricular interstitial region
(magniﬁcation, ×40) in UNX (e), DOCA (f), UNX+AVE (g), DOCA+AVE (h)-treated rats; collagen is stained light red.
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Figure 2: Cumulative concentration—response curves for noradrenaline (a), sodium nitroprusside (b) and acetylcholine (c) in thoracic
aortic rings from UNX (ﬁlled square), UNX+AVE (open square), DOCA (ﬁlled circle) and DOCA+AVE (open circle)-fed rats after 16
weeks of feeding. ∗P <.05 versus UNX.
dimethylformamide with mild heating. Fructose, CS and
BT were obtained through The University of Queensland
Chemical Store.
3. Results
3.1. DOCA-Salt-Induced Rat Model of Cardiac Remodel-
ing (Study I). Hypertension developed in DOCA-salt rats
together with an increased water intake, but these rats failed
to gain weight (Table 1). Avemar treatment did not change
systolic blood pressure and body weight but attenuated
the increased water intake (Table 1). Intake of Avemar,
calculated from the daily food intake, was not signiﬁcantly
diﬀerent between the treated groups: 2.4±0.1 (UNX+AVE)
and 2.3±0.3 (DOCA+AVE) g/kg body wt/day, respectively.
Plasma malondialdehyde concentrations, as a measure of
oxidative stress, were increased in DOCA rats; this increase
was attenuated by Avemar treatment (Table 1).
3.1.1. Cardiac Structure and Function. Hearts from DOCA-
salt rats showed marked cardiac hypertrophy, as evidenced
by increased left ventricular wet weight relative to body
weight and left ventricular mass derived from echocar-
diography (Table 1). This was associated with a decrease
in left ventricular internal diameter, indicating concentric
cardiac hypertrophy (Table 1). Avemar failed to alter the
decrease in left ventricular chamber diameter (Table 1).
Additionally, the relative wet weights of the liver, spleen andEvidence-Based Complementary and Alternative Medicine 5
the remnant kidney from DOCA-salt rats were increased
(Table 1). Treatment with Avemar failed to attenuate the
increased wet weights of the ventricles and the remnant
kidney. Increased wet weight of both liver and spleen were
attenuated with Avemar treatment (Table 1).
Echocardiographic assessment of heart function showed
that Avemar attenuated the increase in relative wall thickness
observed in DOCA-salt rats (Table 1). Furthermore, aortic
blood ﬂow velocities were increased and cardiac output was
decreased in DOCA-salt rats; Avemar prevented the increase
in blood ﬂow velocities but failed to improve cardiac output
(Table 1).
Functionally, the increased diastolic stiﬀness in isolated
hearts from DOCA-salt rats was prevented by Avemar treat-
ment(Table 1).Furthermore,bothinterstitialandperivascu-
lar collagen deposition was increased in the left ventricle of
DOCA-salt rats compared to the UNX rats; this deposition
w a sm a r k e d l ya t t e n u a t e db yA v e m a rt r e a t m e n t( Table 1 and
Figure 1) Spatial location of monocyte/macrophages deter-
mined by hematoxylin and eosin (H&E) staining (Figure 1)
showed monocyte/macrophages in the left ventricle of UNX
rats in very low numbers and always as single cells. The
density of monocyte/macrophages found in the left ventricle
ofDOCA-saltratswassigniﬁcantlygreaterthaninUNX,and
these cells were usually found in clusters of cells located at
scar sites and throughout the interstitium and the areas of
ﬁbrosis. Very few inﬁltrating cells were found in scar tissue
in DOCA-salt rats treated with Avemar, predominantly due
to the decreased area of scar tissue within the left ventricle;
few inﬁltrating cells were found in the perivascular areas
(Figure 1).
3.1.2. Vascular Function. In isolated thoracic aortic rings,
DOCA-salt rats showed decreased contractile responses to
noradrenaline (Figure 2(a)), unaltered responses to sodium
nitroprusside (Figure 2(b)) together with endothelial dys-
function, deﬁned as decreased relaxation responses to acetyl-
choline (Figures 2(c)) .T r e a t m e n tw i t hA v e m a rf a i l e dt o
normalize these decreased responses (Figures 2(a) and 2(c)).
3.2. High-Carbohydrate/High-Fat Diet-Induced Model of Car-
diac Remodeling and Metabolic Changes (Study II). Young
male Wistar rats fed a high-carbohydrate/high-fat diet
showed increased body weight, especially with increased
abdominal fat pads, compared with CS-fed rats, without an
increased food intake (Table 2). Caloric intake was similar
in both diets with CS-fed rats averaging 408±38 kJ/day,
w h e r e a sC A F+B T - f e dr a t sa v e r a g e d3 8 1±47kJ/day. Treat-
ment with Avemar reversed the increase in body weight and
abdominalfatpadscomparedtotheCAF+BT-fedrats.Mea-
surement of blood glucose concentrations after administra-
tion of a loading dose of glucose showed that CAF+BT-fed
rats were glucose-intolerant as the blood glucose concentra-
tions reduced much more slowly than in the corn starch-fed
rats (Table 2). Treatment with Avemar normalized the glu-
cose tolerance compared with CAF+BT-fed rats (Table 2).
3.2.1. Cardiac Structure and Function. Systolic blood pres-
sure increased in CAF+BT-fed rats over the ﬁrst 4 weeks
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Figure 3:Tail-cuﬀmeasurementofsystolicbloodpressurerecorded
at 0, 4, 8, 12 and 16 weeks for corn starch (ﬁlled square), CAF+BT
(ﬁlled circle) and CAF+BT+AVE (open circle)-fed rats. ∗P< .05
versus corn starch-fed rats; #P<.05 versus CAF+BT-fed rats.
and was then maintained over the next 12 weeks with mean
values of 141±6mmHg at 8 weeks and 146±4mmHg
at 16 weeks. In contrast, the systolic blood pressure in
corn starch-fed rats was unchanged at 115±3mmHg at 8
weeks and 117±4mmHg at 16 weeks (Figure 3). Initiating
treatment with Avemar after 8 weeks of CAF+BT feeding
decreased blood pressure to 131±1mmHg at 12 weeks
and 120±2mmHg at 16 weeks (Figure 3). Echocardio-
graphic assessment of CAF+BT-fed rats in vivo indicated
ventricular dilatation (increased internal diameter in dias-
tole) with increased ventricular mass and left ventricular
systolic volume but with decreased contractility shown
as a decreased fractional shortening and ejection fraction
(Table 2). CAF+BT-fed rats showed decreased mitral valve
ﬂow rates (evaluated as a ratio of the ﬂow rate (E/A))
compared with the corn starch-fed rats (Table 2). Ex vivo
cardiac function as measured in the Langendorﬀ isolated
heartshowedamarkedlyincreasedcardiacstiﬀness(Table 2).
These changes in cardiac structure and function were
attenuated by Avemar treatment in the CAF+BT-fed rats
(Table 2).
3.2.2. Organ Remodeling and Oxidative Stress. Post-mortem
organ weights showed a selective increase in left ventricular
wet weight and kidney weights compared with the right ven-
tricleandothermajororgansinCAF+BT-fedratscompared
with corn starch-fed rats (Table 2). Avemar administration
reversedthisorganhypertrophyinCAF+BT-fedrats.Spatial
location of monocyte/macrophages determined by H&E
staining (Figure 4) shows more monocyte/macrophages in
the left ventricle of the CAF+BT rats than in corn starch-
fed rats, and these cells were usually found in clusters of
cells in the interstitial and perivascular regions of ﬁbrosis
(Table 2 and Figure 4). Furthermore, both interstitial and
perivascular collagen deposition was markedly increased in
the left ventricle of CAF+BT-fed rats compared to the
corn starch-fed rats (Table 2 and Figure 4). Plasma malon-
dialdehyde concentrations, as a marker of oxidative stress,
were increased with CAF+BT feeding. Avemar treatment6 Evidence-Based Complementary and Alternative Medicine
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 4: Picrosirius red staining of left ventricular interstitial collagen deposition in corn starch (16 weeks) (a), CAF+BT (8 weeks) (b),
CAF+BT (16 weeks) (c) and CAF+BT+AVE (16 weeks) (d)-treated rats and hematoxylin and eosin staining of inﬁltrating inﬂammatory
cells of left ventricular interstitial region (magniﬁcation, ×40) CS (16 weeks) (e), CAF+BT (8 weeks) (f), CAF+BT (16 weeks) (g) and
CAF+BT+AVE (16 weeks)-treated (h) rats; collagen is stained light red.
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Figure 5: Cumulative concentration-response curves for noradrenaline (a), sodium nitroprusside (b), and acetylcholine (c) in thoracic
aortic rings from corn starch (ﬁlled square), CAF+BT (ﬁlled circle) and CAF+BT+AVE (open circle)-fed rats after 16 weeks of feeding. ∗P
<.05 versus corn starch-fed rats
attenuated these increases in ventricular collagen deposition
and plasma malondialdehyde concentrations (Table 2).
3.2.3. Vascular Responses. Vascular responses to nora-
drenaline were unchanged by CAF+BT feeding. Responses
to sodium nitroprusside (endothelium-independent relax-
ation) were decreased by CAF+BT feeding (Figures 5(a) and
5(b)). CAF+BT feeding induced endothelial dysfunction,
shownasdecreasedresponsestotheendothelium-dependent
relaxant, acetylcholine (Figure 5(c)). Treatment with Avemar
failed to normalize this decreased response to acetylcholine
but normalized the decreased response to sodium nitroprus-
side (Figures 5(b) and 5(c)). Furthermore, Avemar-treated
rats showed decreased responses to noradrenaline compared
with corn starch and CAF+BT-fed rats (Figure 5(a)).
4. Discussion
In the DOCA-salt rat model of hypertension, we have shown
that treatment with Avemar improved cardiac function,
decreased macrophage inﬁltration resulting in decreased
collagen deposition in the ventricular myocardium, reversed
an increased stiﬀness of the left ventricle in the diseased
hearts and attenuated oxidative stress measured as plasma
malondialdehyde concentrations without changing systolic
blood pressure. Our previous studies have shown similarEvidence-Based Complementary and Alternative Medicine 7
Table 2: Physiological parameters of CS, CAF+BT and CAF+BT+AVE-fed rats.
Parameter Corn starch (16 weeks) CAF+BT (8 weeks) CAF+BT (16 weeks) CAF+BT+AVE (16 weeks)
Body weight (g) 341±13 (n = 8) 448±11 (n = 8) 523±14 (n = 8) 479±8( n = 8)
Daily water intake (mL) 24.0±2.4 (n = 6) 19.1±3.0 (n = 6) 21.6±4.0 (n = 6) 19.0±3( n = 6)
Daily food intake (g) 29.0±4.3 (n = 6) 26.1±2.8 (n = 6) 22.4±1.8 (n = 6) 22.0±4( n = 6)
Daily drug intake (g/kg/day) N/A N/A N/A 1.83±0.25 (n = 6)
Fasting plasma glucose
concentrations (mmol/L) 3.2±0.5 (n = 6) 3.5±0.1 (n = 6) 4.0±0.1∗ (n = 6) 3.6±0.1∗∗ (n = 6)
Plasma glucose concentration
(mmol/L) (after 120min glucose
loading)
6.0±0.4 (n = 4) 5.9±0.2 (n = 6) 7.0±0.4∗ (n = 6) 4.4±0.2∗∗ (n = 6)
LVIDd (cm) 0.61 ±0.02 (n = 6) 0.78±0.01∗ (n = 8) 0.76±0.02∗ (n = 8) 0.73±0.01∗ (n = 8)
LVPWd (cm) 0.18 ±0.01 (n = 4) 0.16±0.01 (n = 8) 0.20±0.01 (n = 8) 0.17±0.01 (n = 8)
Fractional shortening (%) 63±2( n = 4) 44±2∗ (n = 8) 35±1∗ (n = 8) 54±2∗∗ (n = 8)
Mitral valve ﬂow rate (E/A) ratio 2.1±0.1 (n = 6) 1.8±0.1 (n = 6) 1.1±0.01∗ (n = 6) 1.4±0.12∗∗ (n = 6)
Estimated LV mass (g) 0.82±0.06 (n = 4) 0.88±0.03 (n = 8) 1.01±0.05∗ (n = 8) 0.82±0.03∗∗ (n = 8)
LV systolic volume (mL) 0.046±0.01 (n = 5) 0.09±0.01∗ (n = 8) 0.127±0.01∗ (n = 8) 0.040±0.01∗∗ (n = 8)
Cardiac output (mL/min) 93±6( n = 4) 98±7( n = 8) 83±9( n = 8) 105±6( n = 8)
Ejection fraction (%) 95±0.9 (n = 4) 81±2∗ (n = 8) 72±1∗ (n = 8) 90±0.9∗∗ (n = 8)
Relative wall thickness 0.55±0.04 (n = 4) 0.41±0.01∗ (n = 8) 0.51±0.04 (n = 8) 0.45±0.01∗∗ (n = 8)
LV—interstitial collagen
(% of total area) 4.8±0.5 (n = 4) 14.6±1.4∗ (n = 4) 19.9±1.2∗ (n = 4) 8.4±0.4∗∗ (n = 4)
LV—perivascular collagen
(% of total area) 21.2±1.6 (n = 4) 31.2±2.6∗ (n = 4) 35.3±3.0∗ (n = 4) 26.1±1.2∗∗ (n = 4)
Diastolic stiﬀness constant (κ) 20.5±0.4 (n = 4) 26.3±2.2∗ (n = 6) 27.8±1.5∗ (n = 6) 21.6±1.4∗∗ (n = 6)
LV+septum (mg/g body wt) 1.9±0.2 (n = 4) 2.1±0.03 (n = 8) 2.2±0.07 (n = 8) 1.7±0.1∗∗ (n = 8)
RV (mg/g body wt) 0.53±0.03 (n = 4) 0.41±0.01∗ (n = 8) 0.43±0.02∗ (n = 8) 0.44±0.02∗ (n = 8)
Liver (mg/g body wt) 26.7±0.6 (n = 4) 28.2±1.4 (n = 8) 29.9±0.95 (n = 8) 23.1±0.02∗∗ (n = 6)
Spleen (mg/g body wt) 2±0.1 (n = 4) 1.8±0.03 (n = 8) 1.68±0.1 (n = 8) 1.75±0.23 (n = 8)
Left and right kidney
(mg/g body wt) 5.15±0.1 (n = 4) 6.3±0.2∗ (n = 8) 5.94±0.12∗ (n = 8) 5.13±0.39∗∗ (n = 8)
Abdominal fat pads
(mg/mm tibial length) 401±56 (n = 6) 343±25 (n = 8) 826±62∗ (n = 8) 339±31∗∗ (n = 8)
Plasma malondialdehyde
(MDA) concentration (μmol/L) 26.9±0.7 (n = 5) 29.4±0.5∗ (n = 5) 32.2±1.2∗ (n = 5) 28.8±0.6∗∗ (n = 5)
Values are mean±SEM; number of experiments in parentheses. LV, left ventricle; RV, right ventricle; LVIDd, left ventricular internal diameter at diastole;
LVPWd, left ventricular posterior wall thickness at diastole. LV mass calculated according to [25]. ∗P < .05 versus CS; ∗∗P < .05 versus CAF+BT.
results with inhibitors of the renin-angiotensin system (cap-
topril, candesartan and spironolactone) [27]. In contrast, we
showed that treatment of DOCA-salt rats with L-arginine
also decreased blood pressure in the DOCA-salt hypertensive
rat [19]. In the current study, we have further shown
that Avemar reversed glucose intolerance, normalized blood
pressure and decreased visceral fat deposition in rats fed a
high-fat/high-carbohydrate diet.
Since the mechanisms for these cardiovascular actions
may be an extension of the anti-oxidant, anti-inﬂammatory
and immunomodulatory mechanisms proposed for the
anti-cancer actions of Avemar, it is worthwhile considering
whether these actions improve cardiovascular function in
disease models (Figure 6). Avemar produced non-speciﬁc
inhibition of both cyclooxygenase isoforms, with IC50
values on COX-1 and COX-2 of 100μg/ml and 300μg/ml,
respectively [30]. In animal studies, COX inhibition
decreased myocardial infarct size [24], produced scar
thinning [31, 32], attenuated cardiopulmonary dysfunction
during endotoxemia [31, 32] and prevented angiotensin
II-induced production of superoxide in cardiovascular
tissue, together with the decrease in systolic blood pressure
and cardiac hypertrophy in vivo [33]. Arachidonic acid
metabolites are important mediators of inﬂammation in
cardiovascular remodeling; arachidonic acid is released from
membranes by phospholipase A2. Inhibition of phospho-
lipase A2 with KH064 prevented an increase in inﬁltration
of inﬂammatory cells, myocardial collagen deposition and
ventricular stiﬀness in young spontaneously hypertensive
rats [29]. Thus, the decreased collagen deposition following
Avemar treatment could be mediated by these known
actions as inhibitors of the production of arachidonic8 Evidence-Based Complementary and Alternative Medicine
Oxidative stress
Antioxidant eﬀects
Immunomodulatory
Anti-inﬂammatory
Avemar
Systolic blood pressure
Glucose intolerance
Cardiovascular
remodelling
Abdominal obesity
Figure 6: Potential mechanisms for the beneﬁcial eﬀects of Avemar
in diet-induced obese rats.
acid metabolites. Further, Avemar decreased inﬂammation
through other immunomodulatory mechanisms, such as
decreased production of pro-inﬂammatory cytokines IL-6
and IL-10 in mice with systemic lupus erythematosus
[20, 34] and decreased macrophage inﬁltration in animal
models of rheumatoid arthritis [20, 34]. Thus, the proposed
mechanisms for the anti-cancer eﬀects of Avemar may
contribute to the cardiovascular responses in this study.
Furthermore, Avemar contains compounds such as ben-
zoquinones and other plant ﬂavonoids, important agents
in controlling oxidative stress and cell damage [19, 34].
There is extensive literature on the therapeutic use of
antioxidant compounds to improve cardiovascular function
[20, 21]. Epidemiological comparisons between populations
and studies within populations also support the contention
that high plasma concentrations or increased dietary intake
of natural antioxidant vitamins may protect against the
development of cardiovascular diseases in humans [20].
Thus, an improvement in oxidative status following Avemar
treatment may improve cardiovascular function.
Since inﬂammatory mediators are important in fat depo-
sition [35], the anti-inﬂammatory mechanisms underlying
the anticancer eﬀects of Avemar may also decrease abdom-
inal fat deposition. Furthermore, peroxisome proliferator-
activated receptor δ (PPARδ) is of central importance
in fat oxidation [35–37]. Flavonoids and phenolic acids
decreased intracellular triglyceride and glucose phosphate
dehydrogenase activity through down-regulating expression
of adipogenic transcription factors such a PPARδ and up-
regulating adiponectin expression [38] .T h ed e c r e a s ei nf a t
deposition and weight gain in the rats fed with a high-
carbohydrate/high-fat diet with Avemar treatment could be
explained by the actions of ﬂavonoids possibly modulating
adipogenic transcription factors.
Similarly, the anti-inﬂammatory mechanisms useful in
treatment of cancer may contribute to the changes in glucose
tolerance in the high-carbohydrate/high fat diet rats treated
with Avemar [39, 40]. Antioxidants such as N-acetylcysteine,
vitamin C and E have also shown anti-diabetic eﬀects pos-
sibly by protecting pancreatic β-cells from glucose toxicity,
stimulating insulin secretion and moderately reducing blood
glucose levels [41–43]. One of the consequences of elevated
blood glucose concentrations is the non-enzymatic glycation
of proteins such as hemoglobin A1c (HbA1c) and serum
albumin [44]. Plant ﬂavonoids inhibited fructose-mediated
glycation of albumin improving the symptoms of diabetes
[44].
Other components of Avemar such as the benzoquinones
may also be cardioprotective. Benzoquinones have very
similar characteristics to vitamins and are anti-oxidant
compounds. Coenzyme Q10 (ubiquinone) is a naturally
occurringbenzoquinone,whichmaypreventcellulardamage
during myocardial ischemia and reperfusion by its roles
in oxidative phosphorylation and membrane stabilization
[45]; diabetes induced a decrease in coenzyme Q plasma
levels [46]. Coenzyme Q10 and alpha-tocopherol treatment
decreased glycated HbA1c and pancreatic lipid peroxidation
in diabetic rats [40]. Coenzyme Q10 has also been used in
oral form to treat various cardiovascular disorders including
angina pectoris, hypertension and congestive heart failure
[45, 47].
In conclusion, our results show that the fermented wheat
germ extract Avemar has a potential role to attenuate the
cardiovascular symptoms induced by hypertension, diabetes
or the metabolic syndrome while moderating metabolic
abnormalities such as glucose tolerance and obesity. Since
Avemar is already available in humans as a complementary
therapy for cancer, this product could be further evaluated
in a clinical setting as an adjunct therapy for preventing
cardiovascular and metabolic symptoms.
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